Recruiting

Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD

ClinicalTrials.gov IDNCT07105345

PhaseNA

Enrollment60

SponsorFar Eastern Memorial Hospital

Age20 Years

SexALL

I'm interested View official listing

Conditions studied

Posttraumatic Stress Disorder

About this study

This study is a longitudinal, multicenter, single-blind, two-arm randomized controlled trial designed to evaluate the effectiveness of Multi-Modal Cognitive Processing Therapy (MMCPT) for individuals with posttraumatic stress disorder (PTSD). Participants will be randomly assigned to either the intervention group receiving MMCPT or a control group receiving treatment-as-usual (TAU). The intervention follows the standard CPT manual developed by Resick and consists of twelve weekly 90-minute individual sessions. The primary outcomes include PTSD symptom severity assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). Secondary outcomes include sleep quality (actigraphy, PSQI), anxiety (STAI), depression (HDRS-17), remission rate, and posttraumatic growth (PTGI). Assessments will occur at baseline, mid-treatment, post-treatment, and at 3-, 6-, 9-, and 12-month follow-ups.

Interventions

Behavioral: Cognitive Processing Therapy (CPT) — Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
Other: Treatment as Usual (TAU) — Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.

Primary outcomes

Change in PTSD symptom severity (CAPS-5) (Baseline (Screening Visit, prior to randomization))
Change in PTSD symptoms (PCL-5) (Baseline, Week 6 ( Mid-treatment), Week 12 (Post-treatment), Month 3, Month 6, Month 9, and Month 12 follow-up)

Eligibility information

Inclusion Criteria: * Aged between 20 and 65 years * Diagnosed with PTSD according to DSM-5 criteria * Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) * Able to provide informed consent * Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment Exclusion Criteria: * Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder * Current substance dependence or abuse within the past 6 months * Severe suicidal ideation or suicide attempt in the past 6 months * Cognitive impairment or neurological disorder affecting participation * Concurrent participation in other psychological treatment for PTSD

Study locations

Far Eastern Memorial Hospital, New Taipei City, Banqiao District 220 Taiwan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.